|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
50681462
???header.onlineuser??? :
266
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"ozyilkan"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
